TY  - JOUR
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Muller, Claude P.
AU  - Scotch, Matthew
AU  - Branch, Donald R.
AU  - Perović, Vladimir R.
AU  - Senćanski, Milan V.
AU  - Veljković, Nevena V.
AU  - Colombatti, Alfonso
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/423
AB  - The worst Ebola virus (EV) outbreak in history has hit Liberia, Sierra Leone and Guinea hardest and the trend lines in this crisis are grave, and now represents a global public health threat concern. Limited therapeutic and/or prophylactic options are available for people suffering from Ebola virus disease (EVD) and further complicate the situation. Previous studies suggested that the EV glycoprotein (GP) is the main determinant causing structural damage of endothelial cells that triggers the hemorrhagic diathesis, but molecular mechanisms underlying this phenomenon remains elusive. Using the informational spectrum method (ISM), a virtual spectroscopy method for analysis of the protein-protein interactions, the interaction of GP with endothelial extracellular matrix (ECM) was investigated. Presented results of this in silico study suggest that Elastin Microfibril Interface Located Proteins (EMILINs) are involved in interaction between GP and ECM. This finding could contribute to a better understanding of EV/endothelium interaction and its role in pathogenesis, prevention and therapy of EVD.
T2  - Frontiers in Microbiology
T1  - In silico analysis suggests interaction between Ebola virus and the extracellular matrix
VL  - 6
DO  - 10.3389/fmicb.2015.00135
ER  - 

@article{
author = "Veljković, Veljko and Glišić, Sanja and Muller, Claude P. and Scotch, Matthew and Branch, Donald R. and Perović, Vladimir R. and Senćanski, Milan V. and Veljković, Nevena V. and Colombatti, Alfonso",
year = "2015",
abstract = "The worst Ebola virus (EV) outbreak in history has hit Liberia, Sierra Leone and Guinea hardest and the trend lines in this crisis are grave, and now represents a global public health threat concern. Limited therapeutic and/or prophylactic options are available for people suffering from Ebola virus disease (EVD) and further complicate the situation. Previous studies suggested that the EV glycoprotein (GP) is the main determinant causing structural damage of endothelial cells that triggers the hemorrhagic diathesis, but molecular mechanisms underlying this phenomenon remains elusive. Using the informational spectrum method (ISM), a virtual spectroscopy method for analysis of the protein-protein interactions, the interaction of GP with endothelial extracellular matrix (ECM) was investigated. Presented results of this in silico study suggest that Elastin Microfibril Interface Located Proteins (EMILINs) are involved in interaction between GP and ECM. This finding could contribute to a better understanding of EV/endothelium interaction and its role in pathogenesis, prevention and therapy of EVD.",
journal = "Frontiers in Microbiology",
title = "In silico analysis suggests interaction between Ebola virus and the extracellular matrix",
volume = "6",
doi = "10.3389/fmicb.2015.00135"
}

Veljković, V., Glišić, S., Muller, C. P., Scotch, M., Branch, D. R., Perović, V. R., Senćanski, M. V., Veljković, N. V.,& Colombatti, A.. (2015). In silico analysis suggests interaction between Ebola virus and the extracellular matrix. in Frontiers in Microbiology, 6.
https://doi.org/10.3389/fmicb.2015.00135

Veljković V, Glišić S, Muller CP, Scotch M, Branch DR, Perović VR, Senćanski MV, Veljković NV, Colombatti A. In silico analysis suggests interaction between Ebola virus and the extracellular matrix. in Frontiers in Microbiology. 2015;6.
doi:10.3389/fmicb.2015.00135 .

Veljković, Veljko, Glišić, Sanja, Muller, Claude P., Scotch, Matthew, Branch, Donald R., Perović, Vladimir R., Senćanski, Milan V., Veljković, Nevena V., Colombatti, Alfonso, "In silico analysis suggests interaction between Ebola virus and the extracellular matrix" in Frontiers in Microbiology, 6 (2015),
https://doi.org/10.3389/fmicb.2015.00135 . .

TY  - JOUR
AU  - Veljković, Milena
AU  - Dopsaj, Violeta
AU  - Dopsaj, Milivoj
AU  - Branch, Donald R.
AU  - Veljković, Nevena V.
AU  - Sakarellos-Daitsiotis, Maria M.
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Colombatti, Alfonso
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4613
AB  - Background: There is convincing evidence from numerous clinical and epidemiological studies that physical activity can reduce the risk for breast and prostate cancer. The biological mechanisms underlying this phenomenon remain elusive. Herein we suggest a role for naturally produced antibodies reactive with the vasoactive intestinal peptide (VIP) in the suppression of breast and prostate cancer, which we believe could offer a possible molecular mechanism underlying control of these cancers by physical exercise. Methodology and Results: We found that sera from individuals having breast and prostate cancers have decreased titers of VIP natural antibodies as demonstrated by a lower reactivity against peptide NTM1, having similar informational and structural properties as VIP. In contrast, sera collected from elite athletes, exhibited titers of natural NTM1-reactive antibodies that are significantly increased, suggesting that physical activity boosts production of these antibodies. Significance: Presented results suggest that physical exercise stimulates production of natural anti-VIP antibodies and likely results in suppression of VIP. This, in turn, may play a protective role against breast and prostate cancers. Physical exercise should be further investigated as a potential tool in the treatment of these diseases.
T2  - PLOS One
T1  - Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy
VL  - 6
IS  - 11
DO  - 10.1371/journal.pone.0028304
ER  - 

@article{
author = "Veljković, Milena and Dopsaj, Violeta and Dopsaj, Milivoj and Branch, Donald R. and Veljković, Nevena V. and Sakarellos-Daitsiotis, Maria M. and Veljković, Veljko and Glišić, Sanja and Colombatti, Alfonso",
year = "2011",
abstract = "Background: There is convincing evidence from numerous clinical and epidemiological studies that physical activity can reduce the risk for breast and prostate cancer. The biological mechanisms underlying this phenomenon remain elusive. Herein we suggest a role for naturally produced antibodies reactive with the vasoactive intestinal peptide (VIP) in the suppression of breast and prostate cancer, which we believe could offer a possible molecular mechanism underlying control of these cancers by physical exercise. Methodology and Results: We found that sera from individuals having breast and prostate cancers have decreased titers of VIP natural antibodies as demonstrated by a lower reactivity against peptide NTM1, having similar informational and structural properties as VIP. In contrast, sera collected from elite athletes, exhibited titers of natural NTM1-reactive antibodies that are significantly increased, suggesting that physical activity boosts production of these antibodies. Significance: Presented results suggest that physical exercise stimulates production of natural anti-VIP antibodies and likely results in suppression of VIP. This, in turn, may play a protective role against breast and prostate cancers. Physical exercise should be further investigated as a potential tool in the treatment of these diseases.",
journal = "PLOS One",
title = "Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy",
volume = "6",
number = "11",
doi = "10.1371/journal.pone.0028304"
}

Veljković, M., Dopsaj, V., Dopsaj, M., Branch, D. R., Veljković, N. V., Sakarellos-Daitsiotis, M. M., Veljković, V., Glišić, S.,& Colombatti, A.. (2011). Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy. in PLOS One, 6(11).
https://doi.org/10.1371/journal.pone.0028304

Veljković M, Dopsaj V, Dopsaj M, Branch DR, Veljković NV, Sakarellos-Daitsiotis MM, Veljković V, Glišić S, Colombatti A. Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy. in PLOS One. 2011;6(11).
doi:10.1371/journal.pone.0028304 .

Veljković, Milena, Dopsaj, Violeta, Dopsaj, Milivoj, Branch, Donald R., Veljković, Nevena V., Sakarellos-Daitsiotis, Maria M., Veljković, Veljko, Glišić, Sanja, Colombatti, Alfonso, "Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy" in PLOS One, 6, no. 11 (2011),
https://doi.org/10.1371/journal.pone.0028304 . .

TY  - JOUR
AU  - Vasiljevic, Nada
AU  - Veljković, Nevena V.
AU  - Kosec, Tatjana
AU  - Ma, Xue-Zhong
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Vujicic, Ana Djordjevic
AU  - Markovic, Ljiljana
AU  - Branch, Donald R.
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4259
AB  - Natural autoantibodies (NAbs) are continually produced throughout life and have an ability to recognize self and altered self, as well as foreign antigens, by recognizing cellular pattern recognition receptors. Sometimes NAb specificity demonstrates overlap between human and pathologic proteomes. This information can be useful in selecting target sequences for screening purposes. In this study we undertook a multi-step bioinformatics search to predict a virus-derived peptide that can be recognized by NAbs in sera of uninfected individuals. We selected protein hepatitis C virus (HCV) NS5A as a target sequence, motivated by the fact that the HCV proteome is characterized by extensive sequence similarities to the human proteome, and because screening for anti-HCV antibodies, including anti-NS5A, is important clinically, particularly in screening of potential blood donors. The virus-specific peptide P1, and the homologous human peptide derived from enzyme-inducible nitric oxide synthase (iNOS), P2, exhibiting not only simple homology, but also complementarities of physicochemical patterns, were synthesized and 80 HCV-negative and 50 HCV-positive blood donor sera were tested by ELISA. These peptides reacted similarly (p LT 0.001) with HCV-negative sera, and in several cases the measured reactivity was significantly above the cut-off value of commercial anti-HCV screening assays. In HCV-positive sera, the titers of antibodies reactive with analyzed HCV NS5A peptide were not significantly increased (p LT 0.001) compared to host peptide, the implications of which are unclear, but may be consistent with these antibodies being naturally produced. Finally, we extended our bioinformatics analyses to the dataset of human self-binding sequences, and propose a general approach for the selection of specific diagnostic and screening antigens for use in immunoassays.
T2  - Viral Immunology
T1  - A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay
VL  - 24
IS  - 2
SP  - 69
EP  - 76
DO  - 10.1089/vim.2010.0107
ER  - 

@article{
author = "Vasiljevic, Nada and Veljković, Nevena V. and Kosec, Tatjana and Ma, Xue-Zhong and Glišić, Sanja and Prljić, Jelena and Vujicic, Ana Djordjevic and Markovic, Ljiljana and Branch, Donald R.",
year = "2011",
abstract = "Natural autoantibodies (NAbs) are continually produced throughout life and have an ability to recognize self and altered self, as well as foreign antigens, by recognizing cellular pattern recognition receptors. Sometimes NAb specificity demonstrates overlap between human and pathologic proteomes. This information can be useful in selecting target sequences for screening purposes. In this study we undertook a multi-step bioinformatics search to predict a virus-derived peptide that can be recognized by NAbs in sera of uninfected individuals. We selected protein hepatitis C virus (HCV) NS5A as a target sequence, motivated by the fact that the HCV proteome is characterized by extensive sequence similarities to the human proteome, and because screening for anti-HCV antibodies, including anti-NS5A, is important clinically, particularly in screening of potential blood donors. The virus-specific peptide P1, and the homologous human peptide derived from enzyme-inducible nitric oxide synthase (iNOS), P2, exhibiting not only simple homology, but also complementarities of physicochemical patterns, were synthesized and 80 HCV-negative and 50 HCV-positive blood donor sera were tested by ELISA. These peptides reacted similarly (p LT 0.001) with HCV-negative sera, and in several cases the measured reactivity was significantly above the cut-off value of commercial anti-HCV screening assays. In HCV-positive sera, the titers of antibodies reactive with analyzed HCV NS5A peptide were not significantly increased (p LT 0.001) compared to host peptide, the implications of which are unclear, but may be consistent with these antibodies being naturally produced. Finally, we extended our bioinformatics analyses to the dataset of human self-binding sequences, and propose a general approach for the selection of specific diagnostic and screening antigens for use in immunoassays.",
journal = "Viral Immunology",
title = "A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay",
volume = "24",
number = "2",
pages = "69-76",
doi = "10.1089/vim.2010.0107"
}

Vasiljevic, N., Veljković, N. V., Kosec, T., Ma, X., Glišić, S., Prljić, J., Vujicic, A. D., Markovic, L.,& Branch, D. R.. (2011). A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay. in Viral Immunology, 24(2), 69-76.
https://doi.org/10.1089/vim.2010.0107

Vasiljevic N, Veljković NV, Kosec T, Ma X, Glišić S, Prljić J, Vujicic AD, Markovic L, Branch DR. A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay. in Viral Immunology. 2011;24(2):69-76.
doi:10.1089/vim.2010.0107 .

Vasiljevic, Nada, Veljković, Nevena V., Kosec, Tatjana, Ma, Xue-Zhong, Glišić, Sanja, Prljić, Jelena, Vujicic, Ana Djordjevic, Markovic, Ljiljana, Branch, Donald R., "A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay" in Viral Immunology, 24, no. 2 (2011):69-76,
https://doi.org/10.1089/vim.2010.0107 . .

TY  - JOUR
AU  - Veljković, Milena
AU  - Branch, Donald R.
AU  - Dopsaj, Violeta
AU  - Veljković, Veljko
AU  - Veljković, Nevena V.
AU  - Glišić, Sanja
AU  - Colombatti, Alfonso
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4495
AB  - Objectives: The incidence of non-AIDS-defining cancer is remarkably higher in HIV-infected than in the general population. In contrast, breast cancer risk is significantly reduced in the HIV-infected population. The molecular mechanisms underlying the phenomenon of suppression of breast cancer in the HIV-infected population may serve as a basis for development of a new platform for prevention and treatment of breast cancer. Hypothesis: Various evidences indicate that vasoactive intestinal peptide (VIP) plays an important role in growth, and differentiation of breast cancer. We previously showed (i) that natural antibodies recognizing VIP and the gp120-derived peptide NTM significantly contribute to the control of HIV disease progression by suppression of VIP-like activity of HIV-1 gp120 and (ii) that physical exercise stimulates production of these natural antibodies. These findings suggest that natural anti-VIP/NTM antibodies could contribute to a decrease of breast cancer in the HIV-infected population by suppression of VIP, which may play a pro/oncogenic function. Aerobic exercise which stimulates production of anti-VIP/NTM antibodies could be used as prevention and supportive treatment of breast cancer. Impact: Immunotherapy based on natural anti-VIP/NTM antibodies could serve as an effective adjunct therapy for the treatment of breast cancer. Similarly, aerobic exercise, which stimulates production of these antibodies, should be considered as an inexpensive and safe preventive and supportive breast cancer therapy. Natural anti-VIP/NTM antibodies also represent promising prognostic marker for breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
VL  - 77
IS  - 3
SP  - 404
EP  - 408
DO  - 10.1016/j.mehy.2011.05.030
ER  - 

@article{
author = "Veljković, Milena and Branch, Donald R. and Dopsaj, Violeta and Veljković, Veljko and Veljković, Nevena V. and Glišić, Sanja and Colombatti, Alfonso",
year = "2011",
abstract = "Objectives: The incidence of non-AIDS-defining cancer is remarkably higher in HIV-infected than in the general population. In contrast, breast cancer risk is significantly reduced in the HIV-infected population. The molecular mechanisms underlying the phenomenon of suppression of breast cancer in the HIV-infected population may serve as a basis for development of a new platform for prevention and treatment of breast cancer. Hypothesis: Various evidences indicate that vasoactive intestinal peptide (VIP) plays an important role in growth, and differentiation of breast cancer. We previously showed (i) that natural antibodies recognizing VIP and the gp120-derived peptide NTM significantly contribute to the control of HIV disease progression by suppression of VIP-like activity of HIV-1 gp120 and (ii) that physical exercise stimulates production of these natural antibodies. These findings suggest that natural anti-VIP/NTM antibodies could contribute to a decrease of breast cancer in the HIV-infected population by suppression of VIP, which may play a pro/oncogenic function. Aerobic exercise which stimulates production of anti-VIP/NTM antibodies could be used as prevention and supportive treatment of breast cancer. Impact: Immunotherapy based on natural anti-VIP/NTM antibodies could serve as an effective adjunct therapy for the treatment of breast cancer. Similarly, aerobic exercise, which stimulates production of these antibodies, should be considered as an inexpensive and safe preventive and supportive breast cancer therapy. Natural anti-VIP/NTM antibodies also represent promising prognostic marker for breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?",
volume = "77",
number = "3",
pages = "404-408",
doi = "10.1016/j.mehy.2011.05.030"
}

Veljković, M., Branch, D. R., Dopsaj, V., Veljković, V., Veljković, N. V., Glišić, S.,& Colombatti, A.. (2011). Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?. in Medical Hypotheses, 77(3), 404-408.
https://doi.org/10.1016/j.mehy.2011.05.030

Veljković M, Branch DR, Dopsaj V, Veljković V, Veljković NV, Glišić S, Colombatti A. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?. in Medical Hypotheses. 2011;77(3):404-408.
doi:10.1016/j.mehy.2011.05.030 .

Veljković, Milena, Branch, Donald R., Dopsaj, Violeta, Veljković, Veljko, Veljković, Nevena V., Glišić, Sanja, Colombatti, Alfonso, "Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?" in Medical Hypotheses, 77, no. 3 (2011):404-408,
https://doi.org/10.1016/j.mehy.2011.05.030 . .

TY  - CONF
AU  - Suck, Garnet
AU  - Veljković, Veljko
AU  - Chu, Sixian
AU  - Niam, Madelaine
AU  - Tan, Suet Mien
AU  - Branch, Donald R.
AU  - Koh, Mickey B. C.
PY  - 2009
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2748
C3  - Journal of Immunology
T1  - Vasoactive intestinal peptide 10-28 enhances natural killer cell cytotoxicity
VL  - 182
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2748
ER  - 

@conference{
author = "Suck, Garnet and Veljković, Veljko and Chu, Sixian and Niam, Madelaine and Tan, Suet Mien and Branch, Donald R. and Koh, Mickey B. C.",
year = "2009",
journal = "Journal of Immunology",
title = "Vasoactive intestinal peptide 10-28 enhances natural killer cell cytotoxicity",
volume = "182",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2748"
}

Suck, G., Veljković, V., Chu, S., Niam, M., Tan, S. M., Branch, D. R.,& Koh, M. B. C.. (2009). Vasoactive intestinal peptide 10-28 enhances natural killer cell cytotoxicity. in Journal of Immunology, 182.
https://hdl.handle.net/21.15107/rcub_vinar_2748

Suck G, Veljković V, Chu S, Niam M, Tan SM, Branch DR, Koh MBC. Vasoactive intestinal peptide 10-28 enhances natural killer cell cytotoxicity. in Journal of Immunology. 2009;182.
https://hdl.handle.net/21.15107/rcub_vinar_2748 .

Suck, Garnet, Veljković, Veljko, Chu, Sixian, Niam, Madelaine, Tan, Suet Mien, Branch, Donald R., Koh, Mickey B. C., "Vasoactive intestinal peptide 10-28 enhances natural killer cell cytotoxicity" in Journal of Immunology, 182 (2009),
https://hdl.handle.net/21.15107/rcub_vinar_2748 .

TY  - JOUR
AU  - Đorđević, Ana
AU  - Veljković, Milena
AU  - Antoni, Sascha
AU  - Sakarellos-Daitsiotis, Maria
AU  - Krikorian, Dimitrios
AU  - Zevgiti, Stella
AU  - Dietrich, Ursula
AU  - Veljković, Nevena V.
AU  - Branch, Donald R.
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3295
AB  - The C-terminus of the second conserved region of HIV-1 gp120 represents a functionally important domain, as it encompasses amino acids directly involved in the binding to the CD4 receptor and in post-receptor binding events. Previous studies have suggested that antibodies with specific affinity to a 23 amino acids-long NTM polypeptide, derived from this HIV-1 gp120 domain, may be involved in the control of HIV disease progression. In the current work, we searched for NTM-recognizing antibodies in specific cohorts of HIV-1 infected individuals, including long-term non-progressors (LTNP) and progressors. For this purpose, we employed a previously defined bioinformatics criterion for design of an NTM peptide mimetic to select an octapeptide, NTMs (FTDNAKTI), which is more suitable for use in a solid-state enzyme-linked immunosorbent assay (ELISA). Our results show that NTMs-reactive antibodies are significantly more prevalent (p LT 0.01) in LTNP as compared to progressors and healthy control subjects, indicating their association with non-progressive infection. The presence of antibodies recognizing the second conserved region of the HIV-1 gp120 derived peptide, NTMs, in LTNP sera suggest that these antibodies could be of considerable interest for development of anti-HIV immune-based therapies and vaccines.
T2  - Current HIV Research
T1  - The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection
VL  - 5
IS  - 5
SP  - 443
EP  - 448
DO  - 10.2174/157016207781662470
ER  - 

@article{
author = "Đorđević, Ana and Veljković, Milena and Antoni, Sascha and Sakarellos-Daitsiotis, Maria and Krikorian, Dimitrios and Zevgiti, Stella and Dietrich, Ursula and Veljković, Nevena V. and Branch, Donald R.",
year = "2007",
abstract = "The C-terminus of the second conserved region of HIV-1 gp120 represents a functionally important domain, as it encompasses amino acids directly involved in the binding to the CD4 receptor and in post-receptor binding events. Previous studies have suggested that antibodies with specific affinity to a 23 amino acids-long NTM polypeptide, derived from this HIV-1 gp120 domain, may be involved in the control of HIV disease progression. In the current work, we searched for NTM-recognizing antibodies in specific cohorts of HIV-1 infected individuals, including long-term non-progressors (LTNP) and progressors. For this purpose, we employed a previously defined bioinformatics criterion for design of an NTM peptide mimetic to select an octapeptide, NTMs (FTDNAKTI), which is more suitable for use in a solid-state enzyme-linked immunosorbent assay (ELISA). Our results show that NTMs-reactive antibodies are significantly more prevalent (p LT 0.01) in LTNP as compared to progressors and healthy control subjects, indicating their association with non-progressive infection. The presence of antibodies recognizing the second conserved region of the HIV-1 gp120 derived peptide, NTMs, in LTNP sera suggest that these antibodies could be of considerable interest for development of anti-HIV immune-based therapies and vaccines.",
journal = "Current HIV Research",
title = "The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection",
volume = "5",
number = "5",
pages = "443-448",
doi = "10.2174/157016207781662470"
}

Đorđević, A., Veljković, M., Antoni, S., Sakarellos-Daitsiotis, M., Krikorian, D., Zevgiti, S., Dietrich, U., Veljković, N. V.,& Branch, D. R.. (2007). The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection. in Current HIV Research, 5(5), 443-448.
https://doi.org/10.2174/157016207781662470

Đorđević A, Veljković M, Antoni S, Sakarellos-Daitsiotis M, Krikorian D, Zevgiti S, Dietrich U, Veljković NV, Branch DR. The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection. in Current HIV Research. 2007;5(5):443-448.
doi:10.2174/157016207781662470 .

Đorđević, Ana, Veljković, Milena, Antoni, Sascha, Sakarellos-Daitsiotis, Maria, Krikorian, Dimitrios, Zevgiti, Stella, Dietrich, Ursula, Veljković, Nevena V., Branch, Donald R., "The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection" in Current HIV Research, 5, no. 5 (2007):443-448,
https://doi.org/10.2174/157016207781662470 . .